abrdn Life Sciences Investors (HQL) Competitors $14.14 +0.06 (+0.39%) Closing price 09/22/2025 03:57 PM EasternExtended Trading$14.14 0.00 (0.00%) As of 09/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HQL vs. BCAT, OXLC, CET, GSBD, MFIC, NMFC, BCSF, BBDC, PFLT, and AWFShould you be buying abrdn Life Sciences Investors stock or one of its competitors? The main competitors of abrdn Life Sciences Investors include BlackRock Capital Allocation Term Trust (BCAT), Oxford Lane Capital (OXLC), Central Securities (CET), Goldman Sachs BDC (GSBD), MidCap Financial Investment (MFIC), New Mountain Finance (NMFC), Bain Capital Specialty Finance (BCSF), Barings Bdc (BBDC), PennantPark Floating Rate Capital (PFLT), and AllianceBernstein Global High Income Fund (AWF). These companies are all part of the "financial services" industry. abrdn Life Sciences Investors vs. Its Competitors BlackRock Capital Allocation Term Trust Oxford Lane Capital Central Securities Goldman Sachs BDC MidCap Financial Investment New Mountain Finance Bain Capital Specialty Finance Barings Bdc PennantPark Floating Rate Capital AllianceBernstein Global High Income Fund BlackRock Capital Allocation Term Trust (NYSE:BCAT) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership. Is BCAT or HQL a better dividend stock? BlackRock Capital Allocation Term Trust pays an annual dividend of $3.39 per share and has a dividend yield of 22.9%. abrdn Life Sciences Investors pays an annual dividend of $1.40 per share and has a dividend yield of 9.9%. Do institutionals & insiders have more ownership in BCAT or HQL? 36.1% of BlackRock Capital Allocation Term Trust shares are owned by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor BCAT or HQL? In the previous week, abrdn Life Sciences Investors had 9 more articles in the media than BlackRock Capital Allocation Term Trust. MarketBeat recorded 10 mentions for abrdn Life Sciences Investors and 1 mentions for BlackRock Capital Allocation Term Trust. BlackRock Capital Allocation Term Trust's average media sentiment score of 1.96 beat abrdn Life Sciences Investors' score of 0.42 indicating that BlackRock Capital Allocation Term Trust is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BlackRock Capital Allocation Term Trust 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive abrdn Life Sciences Investors 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BCAT or HQL more profitable? Company Net Margins Return on Equity Return on Assets BlackRock Capital Allocation Term TrustN/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A Which has more volatility and risk, BCAT or HQL? BlackRock Capital Allocation Term Trust has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, abrdn Life Sciences Investors has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Which has better valuation & earnings, BCAT or HQL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlackRock Capital Allocation Term Trust$159.64M9.97N/AN/AN/Aabrdn Life Sciences InvestorsN/AN/AN/AN/AN/A SummaryBlackRock Capital Allocation Term Trust beats abrdn Life Sciences Investors on 4 of the 7 factors compared between the two stocks. Get abrdn Life Sciences Investors News Delivered to You Automatically Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HQL vs. The Competition Export to ExcelMetricabrdn Life Sciences InvestorsFIN IndustryFinance SectorNYSE ExchangeMarket Cap$406.52M$3.99B$12.73B$21.65BDividend Yield9.94%5.96%5.42%3.50%P/E RatioN/AN/A240.4130.24Price / SalesN/A21.3830.9458.73Price / CashN/A18.7019.8318.30Price / BookN/A1.312.334.66Net IncomeN/A$161.89M$1.01B$1.00B7 Day Performance1.62%0.17%0.66%1.11%1 Month Performance2.50%3.26%1.88%2.95%1 Year Performance-8.95%3.35%540.17%15.18% abrdn Life Sciences Investors Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HQLabrdn Life Sciences InvestorsN/A$14.14+0.4%N/A-9.1%$406.52MN/A0.00N/ABCATBlackRock Capital Allocation Term TrustN/A$15.06-1.5%N/A-9.8%$1.62B$159.64M0.00147,000Positive NewsOXLCOxford Lane Capital1.3791 of 5 stars$17.73+0.2%N/A-33.6%$1.61B$57.31M4.27601CETCentral SecuritiesN/A$50.66-0.2%N/A+13.3%$1.47B$222.17M0.006Positive NewsGSBDGoldman Sachs BDC1.4929 of 5 stars$11.17-1.7%$10.00-10.4%-22.8%$1.30B$161.13M8.86N/APositive NewsMFICMidCap Financial Investment2.5262 of 5 stars$12.24-1.8%$13.30+8.7%-11.2%$1.16B$301.78M11.33N/APositive NewsNMFCNew Mountain Finance3.336 of 5 stars$9.92-5.3%$10.60+6.9%-17.8%$1.11B$89.05M13.05N/AHigh Trading VolumeBCSFBain Capital Specialty Finance3.2261 of 5 stars$15.16-1.9%$16.50+8.8%-14.5%$1.00B$125.44M9.131,000High Trading VolumeBBDCBarings Bdc2.7751 of 5 stars$9.17-1.5%$9.67+5.5%-7.8%$977.98M$112.89M9.5526Positive NewsPFLTPennantPark Floating Rate Capital3.7999 of 5 stars$9.82-3.4%$10.88+10.8%-17.0%$973.83M$89.89M7.01658AWFAllianceBernstein Global High Income FundN/A$11.29+0.5%N/A+1.7%$968.36MN/A0.00N/ANews CoveragePositive News Related Companies and Tools Related Companies BCAT Competitors OXLC Competitors CET Competitors GSBD Competitors MFIC Competitors NMFC Competitors BCSF Competitors BBDC Competitors PFLT Competitors AWF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HQL) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding abrdn Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Share abrdn Life Sciences Investors With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HQL Stock Alerts